Darl D. Flake

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

J. Lanchbury, J. Deloia, T. Krivak, 2012, Gynecologic oncology.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

J. Cuzick, D. Berney, P. Scardino, 2011, The Lancet. Oncology.

External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis

A. Gutin, J. Lanchbury, B. Mabey, 2024, PloS one.

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients

A. Gutin, E. Sasso, J. Lanchbury, 2020, Arthritis Research & Therapy.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

G. Mills, M. Carey, D. Pruss, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

M. Weinblatt, N. Shadick, E. Sasso, 2021, Arthritis Research & Therapy.

Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment

E. Sasso, J. Long, J. Baker, 2020, Clinical Rheumatology.